May 17, 2024 from 12 - 1:30 pm
About the Event
Neuromodulation is the use of medications or technology to alter the activity of neurons to reduce symptoms, improve functioning, and improve quality of life. Over the past year, there have been some changes to the neuromodulation program here at Weill Cornell Medicine and NewYork-Presbyterian.Dr. Dennis Popeo will discuss uses for electroconvulsive therapy beyond mood disorders. Dr. Roy Smetana will discuss the current state of research on the use of ketamine to treat refractory depression and suicidal ideation. Dr. Benjamin Zebley will discuss TMS.
After the presentations, the three presenters will field questions about access to these services and other topics of interest regarding neuromodulation. Please view the continuing education flyer for more information.
Complete the free zoom registration here.
Registration
1.5 CE credit hours are available free of charge to Weill Cornell Medicine Department of Psychiatry full time and voluntary psychology and social work faculty. There is an optional $30 fee for 1.5 CE credit hours for non-Weill Cornell Medicine faculty. CME credits for physicians are not available for this event.
Credits are available to those who sign in with their full name, attend the entire event live, and complete a survey which will be emailed following the completion of the event. Note that the survey must be completed within 30 days of the lecture. Live attendance is required for CE credit hours. No partial credit will be given.
CE credits must be purchased ahead of the event by May 17 at 12pm.
Faculty Speakers
Dennis Popeo, M.D., MSc
Director of Neuromodulation, NewYork-Presbyterian/ Weill Cornell Medical Center
Roy Smetana, M.D., Ph.D.
Director of Neuromodulation, NewYork-Presbyterian Westchester Behavioral Health
Benjamin Zebley, M.D.
Director, Interventional Psychiatry Program, Weill Cornell Medicine
Learning Objectives
- Describe the uses of ketamine, ECT and TMS in patients with other disorders aside from treatment resistant depression.
- Explain the risks and benefits of ketamine, ECT and TMS.
- Discuss the profile of the patient who would best be treated with ketamine, ECT and TMS.
- Describe general mechanism of transcranial magnetic stimulation (TMS) and its effect on the brain.
- Describe recent advances in the field, including the use of MRI-guided neuronavigation to identify brain targets.
References
Brody, B. D., Park, N., Christian, A., Shaffer, C. W., Smetana, R., Kotbi, N., Russ, M. J., & Kanellopoulos, D. (2024). Ketamine for major depressive disorder in during an inpatient psychiatric admission: Effectiveness, adverse events, and lessons learned. Journal of Affective Disorders, 351, 293–298. https://doi.org/10.1016/j.jad.2024.01.207
Connell, J., Oldham, M., Pandharipande, P., Dittus, R. S., Wilson, A., Mart, M., Heckers, S., Ely, E. W., & Wilson, J. E. (2023). Malignant Catatonia: A Review for the Intensivist. J Intensive Care Med, 38(2), 137-150. https://doi.org/10.1177/08850666221114303
Lynch, C. J., Elbau, I. G., Ng, T. H., Wolk, D., Zhu, S., Ayaz, A., Power, J. D., Zebley, B., Gunning, F. M., & Liston, C. (2022). Automated optimization of TMS coil placement for personalized functional network engagement. Neuron, 110(20), 3263–3277.e4. https://doi.org/10.1016/j.neuron.2022.08.012
Financial Disclosures
Drs. Popeo and Smetana have no relevant financial relationships with ineligible companies to disclose but will be discussing off-label use of medication, technology and Ketamine infusions for depression and other mental illnesses. Ketamine infusions (a generic medication made by several companies: Pfizer, J&J, Allergan, Jannsen) are not FDA approved for use in mental illnesses and is used off-label. All views expressed are their own and do not necessarily reflect the opinions of any off-label medication/technology or of Pfizer, J&J, Allergan, or Jannsen. Dr. Zebley has no relevant financial relationships with ineligible companies to disclose. Dr Zebley DOES NOT INTEND to discuss off-label and investigational use of products and services.